Celularity Inc (CELU) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.31 (+3.15%), Market cap $0.03B, 52-week low–high $0.93 ~ $4.15.
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteo
Financial statements, price targets, institutional (13F) holdings and related news for Celularity Inc are updated in real time on BlackAll Trade.
Celularity Inc trades at $1.31 (+3.15%). Real-time quotes and charts are available on BlackAll Trade.
Celularity Inc has a market cap of about $0.03B.
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy produ